ROIV vs RPRX: stock comparison and AI forecast
Roivant Sciences Ltd. (ROIV) and Royalty Pharma Plc (RPRX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ROIV Roivant Sciences Ltd.
- Price
- $35.89 +26.6% · 6M
- Market Cap
- $25.92B
- P/E Ratio
- –
- Size
- large-cap
- AI Forecast
RPRX Royalty Pharma Plc
- Market Cap
- $28.77B
- P/E Ratio
- 38.4x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- RPRX is 1.1 times larger than ROIV by market capitalization ($28.77B against $25.92B).
- RPRX turns 32.1% of its revenue into net income, against -3535.0% for ROIV.
- RPRX carries 1.47 times debt per unit of equity, against 0.09 times for ROIV.
- RPRX yields 1.39% in dividends; ROIV pays none.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ROIV | RPRX |
|---|---|---|
| Market Cap | $25.92B | $28.77B |
| P/E Ratio | – | 38.39x |
| P/B Ratio | 6.13x | 4.21x |
| Dividend Yield | – | 1.39% |
| EPS | $-0.47 | $1.75 |
| Book Value/Share | $5.86 | $15.95 |
| Revenue/Share | $0.01 | $5.92 |
| FCF/Share | $-1.14 | – |
Profitability & Margins
| Metric | ROIV | RPRX |
|---|---|---|
| ROE | -6.3% | 11.9% |
| ROA | -5.0% | 4.1% |
| ROIC | -11.9% | 7.9% |
| Operating Margin | -7914.8% | 59.6% |
| Net Margin | -3535.0% | 32.1% |
| EBT Margin | -3848.7% | 53.2% |
| Tax Rate | -43.0% | 0.0% |
Financial Health
| Metric | ROIV | RPRX |
|---|---|---|
| Current Ratio | 16.72x | 2.80x |
| D/E Ratio | 0.09x | 1.47x |
| Financial Leverage | 1.25x | 2.90x |
| Interest Coverage | 35.9x | 0.7x |
| Working Capital | $4.46B | $1.13B |
Cash Flow
| Metric | ROIV | RPRX |
|---|---|---|
| Operating Cash Flow | -$816M | $2.98B |
| Free Cash Flow | -$821M | – |
| Capital Spending | -$5M | – |
| OCF Growth YoY | – | 23.7% |
| FCF/Sales | -10901.0% | – |
| CapEx/Sales | 61.0% | – |
Operational Efficiency
| Metric | ROIV | RPRX |
|---|---|---|
| Asset Turnover | 0.00x | 0.13x |
| Fixed Assets Turnover | 0.7x | – |
Income Statement
| Metric | ROIV | RPRX |
|---|---|---|
| Total Revenue | $8M | $2.54B |
| Operating Income | -$596M | $1.51B |
| Net Income | -$266M | $815M |
| R&D Expense | $731M | $239M |
Dividend & Shareholder Information
| Metric | ROIV | RPRX |
|---|---|---|
| Dividends Per Share | – | $0.93 |
| Payout Ratio | – | 53.1% |
| Shares Outstanding | 722M | 428M |
| Net Income Growth | – | -20.2% |
| EPS Growth | – | 0.0% |
ROIV vs RPRX: stock comparison and AI forecast
Which is bigger, ROIV or RPRX?
RPRX is 1.1 times larger than ROIV by market capitalization ($28.77B against $25.92B).
Which one does Intratio's AI model rank higher, ROIV or RPRX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.